Poolbeg Pharma, a clinical-stage biopharmaceutical company focusing on infectious and other prevalent diseases with a high unmet medical need, has announced a significant breakthrough in its influenza Artificial Intelligence programme with CytoReason. Poolbeg has been working with CytoReason since March 2022.
The unique disease progression data from influenza human challenge trials combined with CytoReason’s broad repositories of curated disease data were analysed using CytoReason’s industry-leading AI-led platform. The analysis has led to the discovery of multiple novel drug targets for the treatment of influenza.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.